multiple sclerosis

Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?
Endpoints
Wed, 10/30/19 - 10:13 am
Biogen
Alkermes
FDA
multiple sclerosis
MS
Vumerity
Why People With MS Need Permission from Insurers To Take Life-Saving Drugs. It’s Not The Reason You Think.
Forbes
Mon, 10/28/19 - 10:39 am
MS
multiple sclerosis
patients
insurers
payers
drug pricing
Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now
Endpoints
Mon, 10/7/19 - 11:08 am
Acorda Therapeutics
AMPYRA
multiple sclerosis
Supreme Court
Sanofi breaks into digital therapeutics with mental health app for MS patients
Fierce Pharma
Tue, 09/17/19 - 09:57 am
Sanofi
digital therapeutics
Happyify Health
MS
multiple sclerosis
ECTRIMS: Roche's Ocrevus, given early, cuts wheelchair risk by 42%
Fierce Pharma
Sun, 09/15/19 - 09:59 pm
Roche
Ocrevus
multiple sclerosis
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Fierce Pharma
Wed, 09/11/19 - 10:26 am
Biogen
Tecfidera
MS
multiple sclerosis
Novartis takes aim at Roche's star MS drug
Reuters
Fri, 08/30/19 - 10:08 am
Novartis
Roche
multiple sclerosis
Arzerra
ofatumumab
Ocrevus
Does competition equal lower prices? MS drugs defied cost logic as challengers swarmed in
Fierce Pharma
Thu, 08/29/19 - 08:18 pm
multiple sclerosis
MS
drug pricing
Biogen
Roche
Sanofi
Novartis
Teva Pharmaceutical
Bayer
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
Biopharma Dive
Tue, 08/27/19 - 10:55 pm
drug pricing
MS
multiple sclerosis
Medicare
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
Tue, 08/13/19 - 11:43 am
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Tackling the remaining challenges of multiple sclerosis
Pharmaforum
Sat, 08/10/19 - 01:52 pm
Merck KGaA
MS
multiple sclerosis
evobrutinib
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Mon, 08/5/19 - 11:14 am
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
Upcoming events – Atara and Aslan await validating results
EP Vantage
Fri, 08/2/19 - 10:40 am
Atara
Tab-cel
ATA188
multiple sclerosis
Aslan
varlitinib
The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera
Endpoints
Tue, 07/30/19 - 11:29 am
Biogen
Alkermes
MS
multiple sclerosis
Vumerity
clinical trials
Novartis multiple sclerosis product Gilenya approved in China
Pharmaceutical Business Review
Mon, 07/22/19 - 09:45 am
China
Novartis
multiple sclerosis
Gilenya
MediciNova gets bounce after revealing clinical plan for MS therapy
BioCentury
Sat, 07/13/19 - 11:16 am
MedicNova
clinical trials
ibudilast
multiple sclerosis
Atara Reports Initial Data for Multiple Sclerosis Candidate
Yahoo/Zacks.com
Mon, 07/1/19 - 10:18 am
Atara
ATA188
clinical trials
multiple sclerosis
Novartis wins Gilenya reprieve as judge blocks generics, for now
Yahoo/Reuters
Tue, 06/25/19 - 09:20 am
Novartis
generics
Gilenya
multiple sclerosis
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Thu, 06/6/19 - 09:53 am
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Thu, 05/30/19 - 09:42 am
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes

Pages